Lineage Cell Therapeutics
LCTX
66 hedge funds and large institutions have $98.9M invested in Lineage Cell Therapeutics in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 51 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
1.17% less ownership
Funds ownership: 44.86% → 43.69% (-1.2%)
3% less funds holding
Funds holding: 68 → 66 (-2)
26% less capital invested
Capital invested by funds: $134M → $98.9M (-$35M)
80% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 51
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $874K
Top Buyers
| 1 |
Jane Street
New York
|
+$203K |
| 2 |
BG
BlackRock Group
London,
United Kingdom
|
+$80.9K |
| 3 |
Citigroup
New York
|
+$75.9K |
| 4 |
Goldman Sachs
New York
|
+$38.6K |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$33.2K |
Top Sellers
LCTX Hedge Fund Activity: Q1 2016 in Review
66 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2016, worth a combined $98.9M — down 26% from $134M a quarter earlier.
Fund positioning in LCTX was balanced in Q1 2016: 5 funds opened new positions, 5 closed out, 10 added to existing stakes and 51 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $203K. The largest seller was Broadwood Capital, cutting an estimated $3.92M.
- 66 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2016, down from 68 in Q4 2015.
- Funds reported $98.9M of Lineage Cell Therapeutics stock for Q1 2016, down 26% quarter-over-quarter.
- 5 funds opened new Lineage Cell Therapeutics positions in Q1 2016 and 5 closed out, a net change of 0 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2016 was Jane Street, an estimated $203K added.
- The largest Lineage Cell Therapeutics seller in Q1 2016 was Broadwood Capital, an estimated $3.92M sold.
Based on aggregated 13F filings for Q1 2016.